Itb-med Llc

This study tested a new drug called TCD601 (Siplizumab) against a standard treatment (rATG) in 33 kidney transplant patients. The goal was to see if TCD601 is safe and how the body processes it, with the hope of preventing organ rejection. The study was terminated early, so resul…

This study tested a combination of an experimental drug (siplizumab), donor bone marrow cells, and mild chemotherapy in 4 kidney transplant recipients. The goal was to see if this approach could train the body to accept the new kidney without needing lifelong anti-rejection medic…